Related Experiment Video

Updated: Aug 18, 2026

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

Antibody-targeted chemotherapy for the treatment of relapsed acute myeloid leukemia

J P Williams, H L Handler

    The American Journal of Managed Care
    |February 24, 2001
    PubMed

    Insights

    Antibody-targeted chemotherapy (ATC) offers a new approach to cancer treatment by delivering drugs specifically to malignant cells. Gemtuzumab ozogamicin (Mylotarg) is an FDA-approved ATC drug for certain acute myeloid leukemia patients.

    Area of Science:

    • Oncology
    • Pharmacology
    • Immunotherapy

    Background:

    • Acute myeloid leukemia (AML) is a prevalent adult cancer with a poor prognosis.
    • Traditional chemotherapy often causes significant side effects due to non-specific drug delivery.
    • Targeted drug delivery strategies are crucial for improving cancer treatment efficacy and patient outcomes.

    Purpose of the Study:

    • To introduce antibody-targeted chemotherapy (ATC) as a novel cancer treatment modality.
    • To highlight the FDA approval and application of gemtuzumab ozogamicin (Mylotarg) for specific AML patient populations.

    Main Methods:

    • Utilizing antibody-targeted chemotherapy (ATC) to direct antineoplastic drugs to cancer cells.
    • Employing gemtuzumab ozogamicin (Mylotarg), an FDA-approved drug for CD33+ acute myeloid leukemia (AML).

    Main Results:

    • Gemtuzumab ozogamicin (Mylotarg) has received FDA approval for treating CD33+ AML.
    • The drug is indicated for older patients (≥60 years) experiencing their first relapse and ineligible for cytotoxic chemotherapy.

    Conclusions:

    • Antibody-targeted chemotherapy (ATC) represents a significant advancement in cancer therapy.
    • Gemtuzumab ozogamicin (Mylotarg) offers a targeted treatment option for a specific group of AML patients, potentially reducing side effects.

    More Related Videos

    Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy06:51

    Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy

    Published on: December 17, 2019

    Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia08:31

    Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

    Published on: October 17, 2025

    Related Concept Videos

    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against specific...
    Combination Therapies and Personalized Medicine02:50

    Combination Therapies and Personalized Medicine

    Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
    The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...